ArticleReproductive sciences (Thousand Oaks, Calif.)2022
Hsa_circ_0074269-mediated Upregulation of TUFT1 Through miR-485-5p Increases Cisplatin Resistance in Cervical Cancer.
Article in Reproductive sciences (Thousand Oaks, Calif.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 19 citations in OpenAlex.
- Therapy resistance-related ncRNAs in cervical cancer: biomarkers and therapeutic targets.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2026Review
- The emerging role of exosomal circRNAs in modulating apoptotic pathways and overcoming cancer therapy resistance.Discover oncology · 2026Review
- Advances in exosomal non-coding RNAs in cervical cancer (Review).Molecular and clinical oncology · 2025Review
- Construction of a prognostic model for nasopharyngeal carcinoma based on serum exosomal circular RNAs and analysis of immune microenvironment.Clinical and experimental medicine · 2025Article
- TUFT1 regulates cancer progression by suppressing centrosome amplification and mitotic spindle multipolarity.Cell death & disease · 2025Article
- TUFT1 Modulates Cell Proliferation, Migration, Invasion, Stemness and EGFR Signaling in Cervical Cancer through Interacting with and Targeting ATF1.Cell biochemistry and biophysics · 2025Article
- CircVIRMA enhances cell malignant behavior by governing the miR-452-5p/CREBRF pathway in cervical cancer.Naunyn-Schmiedeberg's archives of pharmacology · 2024Article
- Extracellular vesicles and macrophages in tumor microenvironment: Impact on cervical cancer.Heliyon · 2024Review
- Exosomal noncoding RNAs in gynecological cancers: implications for therapy resistance and biomarkers.Frontiers in oncology · 2024Review
- Recent advances of exosomal circRNAs in cancer and their potential clinical applications.Journal of translational medicine · 2023Review
- Clinical Application of Small Extracellular Vesicles in Gynecologic Malignancy Treatments.Cancers · 2023Review
- Circular RNAs in gynecologic cancers: mechanisms and implications for chemotherapy resistance.Frontiers in pharmacology · 2023Review
- Tumor-derived exosomal non-coding RNAs as diagnostic biomarkers in cancer.Cellular and molecular life sciences : CMLS · 2022Review
- The role of long noncoding RNAs in therapeutic resistance in cervical cancer.Frontiers in cell and developmental biology · 2022Review
- The Role and Applications of Exosomes in Gynecological Cancer: A Review.Cell transplantationReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Most cervical cancer patients are prone to developing acquired cisplatin (DDP) resistance. Hsa_circ_0074269 (circ_0074269) plays a promoting role in cervical cancer, but whether circ_0074269 mediates cervical cancer resistance to DDP is unclear. Expression of circ_0074269 was detected by real-time quantitative polymerase chain reaction (RT-qPCR). The half-maximal inhibitory concentration (IC
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.